Revvity Raises 2026 Outlook on Diagnostics Surge, Sells China Unit
RVTY sits 42% above its 52-week low of $81.22.
Summary
Revvity beat Q2 estimates handily — adjusted EPS of $1.41 vs. $1.22 expected, revenue of $730M vs. $709M — and raised full-year guidance above consensus. The diagnostics business drove the beat with 11% growth to $371M, while life sciences dipped 3%. Management cited clear end-market momentum and plans to reinvest tariff refunds into growth. Separately, the company is exiting its China immunodiagnostics business, citing persistent weakness there; the deal is expected to close by end-2027. This follows the earlier Q2 release and adds the China divestiture and segment-level color. Thermo Fisher's recent upbeat commentary reinforces the life sciences recovery narrative.
At the time of this announcement, RVTY was trading at $115.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $81.22 to $118.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.